It's been nearly 15 years since the FDA cleared Amevive (alefacept) for use in psoriasis, making it one of the first biologic drugs approved for a dermatologic disease and ushering in a new wave of therapies that has not only transformed the treatment paradigm for psoriasis patients but also proved to big pharma that targeting skin conditions could be a lucrative venture.